SCHEMBL2862796

SCHEMBL2862796

O=C(O)C(O)Cc1cccc(O)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM6B O15054 1/20 0.61
GRIA2 P42262 1/20 0.55
CTBP2 P56545 1/20 0.47
ENPP2 Q13822 1/20 0.47
HIF1A Q16665 2/20 0.45
KYNU Q16719 1/20 0.45
DRD2 P14416 1/20 0.44
DRD1 P21728 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44
LMNA P02545 1/20 0.44
IDO1 P14902 1/20 0.44
KDM4E B2RXH2 1/20 0.44
OPRK1 P41145 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
PKM P14618 1/20 0.43
ALOX15 P16050 1/20 0.43
NFKB1 P19838 1/20 0.43
MAPK1 P28482 1/20 0.43
ANPEP P15144 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2865019 1.00 KDM6B (0.61) KDM6BGRIA2CTBP2ENPP2HIF1A
SCHEMBL491093 0.85 GRIA2 (0.58) GRIA2CTBP2ENPP2HIF1ADRD2
SCHEMBL19369761 0.84 GRIA2 (0.50) KDM6BGRIA2CTBP2ENPP2HIF1A
SCHEMBL9748709 0.83 MDM2 (0.50) KDM6BGRIA2CTBP2ENPP2HIF1A
SCHEMBL8592637 0.81 KDM6B (0.56) KDM6BCTBP2LMNA
SCHEMBL3347144 0.81 KDM6B (0.56) KDM6BCTBP2LMNA
SCHEMBL19361721 0.81 GRIA2 (0.44) KDM6BGRIA2CTBP2ENPP2HIF1A
SCHEMBL458080 0.80 GRIA2 (0.82) GRIA2HIF1AKDM4EPKMALOX15
SCHEMBL20702768 0.80 KDM6B (0.54) KDM6BTAAR1
SCHEMBL8953473 0.80 SLC1A1 (0.62) KDM6B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230398158-A1 NEW COMPOSITION FOR TREATMENT OF SKIN CONDITIONS LACTOBIO A/S (DK) 2023-12-14 US claimed
EP-4240826-A1 NEW COMPOSITION FOR TREATMENT OF SKIN CONDITIONS Lactobio A/S (DK) 2023-09-13 EP claimed
CN-116568292-A Novel compositions for treating skin disorders 莱托生物股份有限公司 2023-08-08 CN claimed
WO-2022096573-A9 NEW COMPOSITION FOR TREATMENT OF SKIN CONDITIONS LACTOBIO A/S (DK) 2022-10-27 WO claimed
WO-2022096573-A1 NEW COMPOSITION FOR TREATMENT OF SKIN CONDITIONS LACTOBIO A/S (DK) 2022-05-12 WO claimed
EP-3102053-A1 SYSTEMS, METHODS, AND COMPOSITIONS FOR PROMOTING PATHOGEN CONTROL AND FOOD PRESERVATION Micro-nature LLC (US) 2016-12-14 EP claimed
US-20160338361-A1 SYSTEMS, METHODS, AND COMPOSITIONS FOR PROMOTING PATHOGEN CONTROL AND FOOD PRESERVATION MICRO-NATURE LLC (US) 2016-11-24 US claimed
US-20160029667-A1 IMPROVED MEAT SLURRY METHODS OF PRODUCTION AND COMPOSITIONS MICRO-NATURE, LLC 2016-02-04 US claimed
WO-2015120100-A1 SYSTEMS, METHODS, AND COMPOSITIONS FOR PROMOTING PATHOGEN CONTROL AND FOOD PRESERVATION MICRO-NATURE LLC (US) 2015-08-13 WO claimed
EP-0770399-A2 Additives enhancing topical actions of therapeutic agents Van Scott, Eugene J., Dr. (US) 1997-05-02 EP claimed
US-20240350561-A1 PROBIOTIC BACTERIA COMPOSITION FOR INHIBITING FUNGAL PROLIFERATION LACTOBIO A/S (DK) 2024-10-24 US disclosed
EP-4392048-A1 PROBIOTIC BACTERIA COMPOSITION FOR INHIBITING FUNGAL PROLIFERATION Lactobio A/S (DK) 2024-07-03 EP disclosed
CN-118139633-A Probiotic composition for inhibiting fungal proliferation 莱托生物股份有限公司 2024-06-04 CN disclosed
US-20230398158-A1 NEW COMPOSITION FOR TREATMENT OF SKIN CONDITIONS LACTOBIO A/S (DK) 2023-12-14 US disclosed
EP-4240826-A1 NEW COMPOSITION FOR TREATMENT OF SKIN CONDITIONS Lactobio A/S (DK) 2023-09-13 EP disclosed
EP-1873141-A1 CALCIUM BIS[2S)-3-[3-(2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2- FLUOROPROPOXY¨PHENYL]-2-ISOPROPOXYPROPIONATE] AND INTERMEDIATE THEREOF Eisai R&D Management Co., Ltd. (JP) 2008-01-02 EP disclosed
US-20070117866-A1 Calcium bis [ (2S) - 3- [3-[ (2S) -3- (4-chloro-2-cyanophenoxy) -2- fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof EISAI CO., LTD. (JP) 2007-05-24 US disclosed
US-20070117866-A1 Calcium bis [ (2S) - 3- [3-[ (2S) -3- (4-chloro-2-cyanophenoxy) -2- fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof EISAI CO., LTD. (JP) 2007-05-24 US disclosed
US-20070117866-A1 Calcium bis [ (2S) - 3- [3-[ (2S) -3- (4-chloro-2-cyanophenoxy) -2- fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof EISAI CO., LTD. (JP) 2007-05-24 US disclosed
EP-0599819-B1 Use of hydroxycarboxylic acids and derivatives for the preparation of topical dermatologic compositions for the treatment of wrinkles SCOTT EUGENE J VAN (US) 1997-04-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117866-A1 Calcium bis [ (2S) - 3- [3-[ (2S) -3- (4-chloro-2-cyanophenoxy) -2- fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof CA2, CACNA1A, CACNA1C KDM6B 2870/4885GRIA2 1598/4885CTBP2 1540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.